Oncology and Hematology

Episodes 1-16 of 53

• 

  RestartResume

  The Evolving Landscape of Resectable Locally Advanced HNSCC

  RestartResume

  The Evolving Landscape of Resectable Locally Advanced HNSCC

  MinuteCE®

  The Evolving Landscape of Resectable Locally Advanced HNSCC

  0.75 program credits

  • 

    

    Ravindra Uppaluri, MD, PhD

  0.75 program credits

• 

  RestartResume

  Multidisciplinary Collaboration Facilitates Multimodality Therapy

  RestartResume

  Multidisciplinary Collaboration Facilitates Multimodality Therapy

  MinuteCE®

  Multidisciplinary Collaboration Facilitates Multimodality Therapy

  0.75 program credits

  • 

    

    Douglas Adkins, MD

  • 

    

    Ravindra Uppaluri, MD, PhD

  • 

    

    Nancy Lee, MD, FASTRO

  0.75 program credits

• 

  RestartResume

  Emerging Evidence for Perioperative ICIs in Locally Advanced HNSCC

  RestartResume

  Emerging Evidence for Perioperative ICIs in Locally Advanced HNSCC

  MinuteCE®

  Emerging Evidence for Perioperative ICIs in Locally Advanced HNSCC

  0.75 program credits

  • 

    

    Ravindra Uppaluri, MD, PhD

  0.75 program credits

• 

  RestartResume

  Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative Immunotherapy

  RestartResume

  Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative Immunotherapy

  CME/CE

  Resectable Head & Neck Cancer: A Team-Based Approach to Perioperative Immunotherapy

  0.25 credits

  • 

    

    Robert Haddad, MD

  • 

    

    Ravindra Uppaluri, MD, PhD

  • 

    

    Nancy Lee, MD, FASTRO

  0.25 credits

• 

  RestartResume

  Rationale for Combining Radiation and Immunotherapy in Resectable Locally Advanced HNSCC

  RestartResume

  Rationale for Combining Radiation and Immunotherapy in Resectable Locally Advanced HNSCC

  MinuteCE®

  Rationale for Combining Radiation and Immunotherapy in Resectable Locally Advanced HNSCC

  0.75 program credits

  • 

    

    Nancy Lee, MD, FASTRO

  0.75 program credits

• 

  RestartResume

  Applying Perioperative ICIs in Clinical Practice

  RestartResume

  Applying Perioperative ICIs in Clinical Practice

  MinuteCE®

  Applying Perioperative ICIs in Clinical Practice

  0.75 program credits

  • 

    

    Douglas Adkins, MD

  0.75 program credits

• 

  RestartResume

  Managing Immune-Related Adverse Events in the Perioperative Setting 

  RestartResume

  Managing Immune-Related Adverse Events in the Perioperative Setting 

  MinuteCE®

  Managing Immune-Related Adverse Events in the Perioperative Setting 

  0.75 program credits

  • 

    

    Douglas Adkins, MD

  0.75 program credits

• 

  RestartResume

  Risk Stratification and Patient Selection for Perioperative ICIs

  RestartResume

  Risk Stratification and Patient Selection for Perioperative ICIs

  MinuteCE®

  Risk Stratification and Patient Selection for Perioperative ICIs

  0.75 program credits

  • 

    

    Douglas Adkins, MD

  0.75 program credits

• 

  MinuteCE®

  Advancing Care in Locally Advanced HNSCC: Integrating Perioperative Immunotherapy and Multimodal Strategies

  0.75 credits 7 episodes

  • 

    

    Douglas Adkins, MD

  • 

    

    Ravindra Uppaluri, MD, PhD

  • 

    

    Nancy Lee, MD, FASTRO

  0.75 credits 7 episodes

• 

  RestartResume

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  RestartResume

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  MinuteCE®

  Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Expert Recommendations and Key Takeaways

  RestartResume

  Expert Recommendations and Key Takeaways

  MinuteCE®

  Expert Recommendations and Key Takeaways

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  MinuteCE®

  Breaking Barriers in AML: Risk Stratification, Molecular Profiling, and Novel Menin-Directed Treatment Options

  1.00 credit 10 episodes

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Managing Adverse Events Associated With Menin Inhibitors 

  RestartResume

  Managing Adverse Events Associated With Menin Inhibitors 

  MinuteCE®

  Managing Adverse Events Associated With Menin Inhibitors 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Stratifying Risk to Guide Therapy in R/R AML 

  RestartResume

  Stratifying Risk to Guide Therapy in R/R AML 

  MinuteCE®

  Stratifying Risk to Guide Therapy in R/R AML 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  RestartResume

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  MinuteCE®

  Ongoing Clinical Trials in AML With Menin Inhibitors 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit

• 

  RestartResume

  Menin Inhibitors: Biologic and Clinical Rationale 

  RestartResume

  Menin Inhibitors: Biologic and Clinical Rationale 

  MinuteCE®

  Menin Inhibitors: Biologic and Clinical Rationale 

  1.00 program credit

  • 

    

    Ghayas Issa, MD

  • 

    

    Amir Fathi, MD

  1.00 program credit